Prana appoints US analyst to board
Thursday, 25 March, 2004
Melbourne biotech company Prana Biotechnology (ASX: PBT) has appointed leading US biotech analyst Dr Jonas Alsenas to its board of directors.
Most recently, Alsenas managed a hedge fund with an emphasis on biotechnology for ING Investment Management, New York.
"[Alsenas] is held in high regard in the international biotech sector and possesses an extensive knowledge of the industry in which Prana operates. Hi understanding of, and fundamental belief in, our technology and business strategy will help to shape Prana's future," said Prana CEO Geoffrey Kempler.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
